Navigation Links
InterMune Reports Second Quarter 2014 Financial Results and Business Highlights
Date:8/6/2014

is of NAC administered on top of pirfenidone.  Results will be reported by the end of 2015.  The PANORAMA trial was initially designed to enroll up to 250 patients at approximately 70 centers in Europe for a treatment period of six months. 
  • Based on regulatory progress noted above, InterMune has accelerated its efforts to build its commercial infrastructure to be prepared to launch pirfenidone in the United States in the fourth quarter of 2014 (previously targeted for the first quarter of 2015), assuming FDA approval during the fourth quarter of 2014. 
  • InterMune currently anticipates that the U.S. commercial organization will consist of approximately 175 ‎employees.  InterMune expects that the build-out of the U.S. commercial organization will be substantially completed by the end of the third quarter of 2014.
  • Additionally, InterMune currently expects its U.S. Medical Affairs staff to consist of approximately 35 personnel including field-based medical science directors and staff and professionals managing medical education, medical information, scientific communications and publications, clinical trials and patient registries.
  • In June and July 2014, InterMune completed the exchange of approximately $43.1 million and $52.9 million, respectively, of its 2.50% convertible notes due 2017 for shares of its common stock and $16.9 million of its 5.00% convertible notes due 2015 for shares of its common stock.
  • Second Quarter 2014 Financial Results (Unaudited)InterMune reported total Esbriet revenue in the second quarter of 2014 of $35.7 million, compared with $14.4 million in the second quarter of 2013, an increase of 148 percent.  Sequentially, Esbriet revenue in the second quarter of 2014 increased 18 percent from $30.3 million in the first quarter of 2014.  InterMune reported total revenue for the first six months of 2014 of $66.0 million, compared with $24.9 million in the first six
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
    2. InterMune Announces Proposed Public Offering of Common Stock
    3. InterMune Reports Second Quarter 2013 Financial Results And Business Highlights
    4. Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
    5. InterMune Announces Presentations of New Research in IPF at ERS
    6. InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
    7. InterMune to Divest Actimmune® (Interferon Gamma-1b)
    8. Neurocrine Biosciences Reports Second Quarter 2014 Results
    9. Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2015
    10. China Biologic Reports Financial Results for the Second Quarter of 2014
    11. Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
    (Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
    (Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
    Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
    ... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
    ... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
    Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
    (Date:9/1/2015)... New Jersey (PRWEB) , ... September 01, 2015 , ... ... one of the 50 Best Companies for Latinas in the LATINA Style 50 Report ... United States. , For 2015, Horizon BCBSNJ climbs from number 24 ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... and prevent different malignancies. Some options for cancer treatment are available belonging ... which distinctive approach is necessary for effective treatment. Several molecules have been ...
    (Date:9/1/2015)... ... September 01, 2015 , ... As part of its ongoing ... of Minnesota (Blue Cross) has announced Doctor On Demand as the company’s preferred ... On Demand provides immediate access to Board Certified physicians or next-day appointments with ...
    (Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure ... inside a wound to remove exudates, fluid, and infectious materials to prepare the ... stand-alone devices, disposable devices, and canisters, etc.) is projected to expand continuously through ...
    (Date:9/1/2015)... TX (PRWEB) , ... September 01, 2015 , ... ... that it is now offering the MonaLisa Touch® , an innovative vaginal ... The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition ...
    Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
    ... Oct. 5 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ... in the manufacture, research, development, marketing and,distribution of ... announced underwritten public offering. The Company sold 4,600,000,shares ... in its public offering,resulting in approximately $65.5 million ...
    ... Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) ... grant to Los Angeles Biomedical Research Institute at Harbor-UCLA ... penile endogenous (adult) stem cells with the company,s drug, ... the drug to provide long-term correction of male erectile ...
    ... monitoring over whole-brain radiotherapy , MONDAY, Oct. 5 ... learning and memory problems when whole-brain radiation therapy ... researchers have found. , SRS delivers narrowly focused ... The study included 58 patients with one to ...
    ... warns World Vision , - World Vision to open 13 ... calls on Indonesian government to prioritize its relief efforts to ... schoolchildren in Indonesia,s West Sumatra quake zone were called back ... of children affected by last week,s earthquake remain the disaster,s ...
    ... ... company, is launching its second "Boost Your Juice Contest" in October, in which healthcare ... win a free Internet marketing campaign worth up to $5,000. , ... Phoenix, AZ (PRWEB) October 5, 2009 ...
    ... Extent of the Prematurity Crisis Still Unknown, March of Dimes Says ... one million infants die each year because they are born too ... and Regional Toll of Preterm Birth. , The new White ... were born preterm -- defined as birth at less than 37 ...
    Cached Medicine News:Health News:China-Biotics, Inc. Announces Closing of Public Offering of Common Stock 2Health News:China-Biotics, Inc. Announces Closing of Public Offering of Common Stock 3Health News:ESAI provides grant to LA BioMed to investigate long-term correction of erectile dysfunction 2Health News:Focused Radiation Protects Tumor Patients' Brain Function 2Health News:As Schools Reopen in Indonesia, World Vision Says Children's Basic Needs Still Not Being Met 2Health News:Vertical Measures Announces its Version of Healthcare Reform by Giving Away 5K in Internet Marketing Services 2Health News:Vertical Measures Announces its Version of Healthcare Reform by Giving Away 5K in Internet Marketing Services 3Health News:Global Death Toll: One Million Premature Babies Every Year 2Health News:Global Death Toll: One Million Premature Babies Every Year 3Health News:Global Death Toll: One Million Premature Babies Every Year 4Health News:Global Death Toll: One Million Premature Babies Every Year 5
    ... The SeedVac™ is a vacuum driven device designed to ... tube tip. Seeds are drawn into the clear tube ... the hand piece to create the vacuum. The prescribed ... the clear tube tip before being placed into the ...
    MT-BT-5001-25 prostate seeding needle (set of 25 unloaded needles).,MT-BT-5001-P prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seeding...
    ... a myoma was performed with a cutting ... vaporization of myomas with the VaporTrode Vaporization ... tissue chips that obscure visibility. No tissue ... This unique design provides areas of high ...
    ... The 19 Fr. OES 4000 Nephroscope, with ... quality with outstanding durability. The lumbotome, for ... the telescopic bougies, allow safer access. The ... comprehensive range of grasping forceps and lithotripsy ...
    Medicine Products: